Skip to main content
. 2020 Dec 4;15(12):e0233073. doi: 10.1371/journal.pone.0233073

Fig 1. Dose-related neflamapimod (NFMD) subacute treatment effects on mNSS of rats with tMCAO.

Fig 1

The study included three groups: vehicle (Pluronic F108; n = 18), 1.5 mg/kg neflamapimod (n = 21), and 4.5 mg/kg neflamapimod (n = 21). (A) Mean±SD mNSS value at Day 2, Week 4 and Week 6. Both at Week 4 and Week 6, the mean±SD mNSS values were decreased and significantly lower in each neflamapimod dose group when compared to vehicle. In addition, a dose response effect on improvement in neurologic function was indicated by the lower mean±SD mNSS value in the 4.5 mg/kg neflamapimod dose group when compared to that of the 1.5 mg/kg dose group. (B) Absolute changes in mNSS±SD from Day 2 to Week 4 and Day 2 to Week 6. Significant mNSS differences were observed at both time point comparisons for 1.5 or 4.5 mg/kg neflamapimod dose groups compared to vehicle compared. Significance of between group differences was assessed using a two-way analysis of variance (ANOVA) with a Bonferroni correction (*P<0.05; **P<0.01; ***P<0.001; see text for exact P-values>0.001).